RESEARCH. AgeCap is the only Swedish partner in a new European cooperation to examine how to better measure the effects of drugs used to fight Alzheimer’s disease. These efforts may ultimately lead to better medicines.
The project is called ROADMAP, which is an acronym for “Real world Outcomes across the Alzheimer’s Disease spectrum for better care: Multi-modal data Access Platform”, and it recently kicked off with a meeting in Barcelona.
“Most exciting was the very open-minded dialogue between academia and industry. The project also includes prominent statisticians, who will provide us with very interesting analyses of our studies,” says Ingmar Skoog, who heads the AgeCap strategic research center. AgeCap has been invited to participate in ROADMAP and is the only Swedish partner involved in the project.
Better metrics and better cooperation
The project is funded under the EU framework program Horizon 2020 and the organization European Pharmaceutical Industry. The purpose of ROADMAP is both to find better ways to measure the effects of Alzheimer’s drugs and to improve cooperation between academia and the European pharmaceutical industry. The project is led from Oxford and includes most of the major pharmaceutical companies in Europe. In the longer term, it is hoped that ROADMAP will lead to better pharmaceuticals against Alzheimer’s.
ROADMAP will use databases from drug trials, clinical studies, and population studies to see the real-world progression of Alzheimer’s.
“Our H70 studies and studies from the UK have been selected as the most appropriate population studies and will be used to test various models and statistical analyses as a way of developing models of Alzheimer’s. We are also considered to have the best expertise for assessing results, and we provide advice on how to proceed with further studies,” says Ingmar Skoog.
For more information about ROADMAP: http://www.roadmap-alzheimer.org/
For more information about AgeCap: http://agecap.gu.se/
TEXT: ELIN LINDSTRÖM CLAESSEN
PHOTO: JOHAN WINGBORG/GU